treatment option for pain relief, besides treatment with oral non-steroidal anti-inflammatory (NSAIDs) before starter biotechnological treatment. However, there are few studies to evaluate efficacy of this technique with a small number of patients and a short follow-up. Ultrasonography has been used as a valuable option to guide this technique.

Objectives: To evaluate the efficacy and safety of ultrasound-guided injections of sacroiliac joints (SIJs) in patients with sacroiliitis using clinical and laboratory outcomes at baseline and at 4-6th weeks.

Methods: This study involved patients with axSpA with acute sacroiliitis, ≥ 18 and ≤ 65 years old, with body mass index (BMI) $< 30\text{ kg/m}^2$ attending the Rheumatology Outpatient Clinic, which had been poorly controlled (ASDAS > 2.1) by conventional therapy (physiotherapy, NSAIDs at maximum tolerated dosing during ≥ 4 weeks). Sociodemographic, clinical (disease duration, BMI, BASDAI, BASFI, ASDAS) and laboratory (CRP) data was collected from the medical records at baseline and at 4-6th weeks.

Statistical analyses were conducted using SPSS version 25. Continuous variables were described with mean/median $\pm$ standard deviation (SD).

SIJs injection was performed, under ultrasound guidance, using standard procedures with 2mL of lidocaine 1% and 40mg of methylprednisolone, with a 22-gauge needle. The procedure was performed by the same operator. Written informed consents were obtained from all patients.

Results: We performed eleven sacroiliac injection in eleven consecutive patients (one procedure per patient). Nine patients (81.8%) were female, mean age ($\pm$ SD) of 40.6(± 9.4) years, median disease duration($\pm$ SD) of 0.9(± 6.2) years and median BMI($\pm$ SD) of 24.2(± 3.3). Eight patients (72.7%) had Nr-axSpA. All patients were non-responders to NSAIDs.

At 4-6th weeks there was a decreased in median ($\pm$ SD) BASDAI (5.4 $\pm$ 1.9 vs 4.1 $\pm$ 1.9), BASFI (4.2 $\pm$ 1.4 vs 3.5 $\pm$ 2.3) and ASDAS (3.2 $\pm$ 0.8 vs 2.2 $\pm$ 0.6) indexes.

Conclusion: As previous studies demonstrated, this technique seems to be safe and quite effective.

Our goal is to increase the number of patients undergoing this technique and have a longer follow up to evaluate its efficacy. The study has several limitations: the mid- and long-term effects should be evaluated in the future based on the results of the short-term effects and the study was not conducted as a double-blinded, controlled study.

References:

- [1] van der Heijde D, Burgos-Vargas R, Ramiro S, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2017; 76:978–991
- [2] Maugars Y, Mathis C, Vilon P, Prost A. Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. *Arthritis Rheum* 1992; 35:564–8.
- [3] Pekkaiah MZ, Kiralp MZ, Baskim CC et al. Sacroiliac joint injections performed with sonographic guidance. *J Ultrasound Med* 2003;22:553–9
- [4] Klauser A, De Zordo T, Feuchtnner G et al. Feasibility of ultrasound-guided sacroiliac joint injection considering sonoanatomic landmarks at two different levels in cadavers and patients. *Arthritis Rheum* 2008; 59:1618–1624.

Disclosure of Interests: Ana Rita Cunha: None declared, Carolina Mazeda: None declared, Renata Aguiar: None declared, Anabela Barcelos Speakers bureau: Bene, Eli-Lilly, Pfizer, MSD, Novartis

DOI: 10.1136/annrheumdis-2020-eular.6133

AB0643

DRUG SURVIVAL OF SECUKINUMAB IN A SPONDYLOARTHRITIS COHORT. A 24 MONTHS MULTICENTRIC STUDY

P. Navarro Alonso¹, Á. García Martos², A. Castilla³, L. González², M. D. C. Ortega⁴, C. Arconada⁴, A. Prada-Ojeda⁵, L. Sala Icardo⁵, L. Barrio Nogal⁵, E. M. Andres⁶, A. Diaz Oca¹. ¹HU Fuenlabrada, Madrid, Spain; ²HU del Tajo, Aranjuez, Spain; ³HU La Paz, Madrid, Spain; ⁴HU Infanta Elena, Valdemoro, Spain; ⁵HU Torrejon, Torrejon de Ardoz, Spain; ⁶Universidad Rey Juan Carlos, Madrid, Spain

Background: Secukinumab inhibits the interaction between Interleukin 17A (IL-17A) and its receptor. Clinical trials have demonstrated good data in efficacy and safety in patients with spondyloarthritis (SpA) as first biological choice or inadequate response to other biological in SpA. However there is few evidence in real clinical practice.

Objectives: Evaluate the drug survival in a real clinical practice, as an indirect way to show the efficacy and security of Secukinumab at 24 months

Methods: A multicentric observational, longitudinal, retrospective study of 24 months conducted in five Madrid hospitals (Spain). Patients older than 18 years treated with Secukinumab which fulfilled ASAS criteria for SpA and/or modified New York criteria for ankylosing spondylitis (AS) and/or CASPAR criteria for psoriatic arthritis (PsA) were included. For evaluation of the drug survival, dates from starting until closing date or definite withdrawal of the

treatment were determined. Kaplan-Meier function was used to estimate the drug survival and Wilcoxon test for the comparison of the survival rate between the different diagnoses, because of the survival curves did not reach the median

Results: A total of 71 patients were included. The mean age was 50.26 ys (SD 11.01), 57.75% women. 35 patients fulfilled classification criteria for PsA and 36 fulfilled classification criteria for axSpA. 22 patients were naïve for biologic therapies and 49 patients had an inadequate response to TNFi. 13 patients discontinued Secukinumab before the closing date, the main reason for the interruption was secondary failure (n= 6), and primary failure (n=2). Secukinumab survival rate was 81.95% up to 24 months in this cohort. The median of survival was 2.36 years (IC: 1.79-2.84). There were no significant differences about the drug survival related to diagnosis (p=0.976). The safety data were similar to those described in clinical trials.

Conclusion: Secukinumab is an effective and safe treatment for the management of espondiloarthritis regardless of the subtypes, with a high survival rate. In this study naïve patients show similar data obtained in clinical trials. In this cohort of patients, those who initiated secukinumab after failure to TNFi, showed a greater secukinumab survival than the data provided in clinical trials

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.3666

AB0644

ULTRASOUND GUIDED EPIDURAL INJECTION IN RADIOGRAPHIC AXIAL SPA PATIENTS WITH LIMITED SPINE MOBILITY: A PROSPECTIVE PILOT RANDOMIZED CONTROLLED TRIAL

A. Hamed¹, A. Radwan², O. Sayed³, A. Elsamani⁴. ¹Minya University, Minya, Egypt; ²Sohag University Hospital, Rheumatology and Rehabilitation Department, Sohag, Egypt; ³Minya University, Rheumatology and Rehabilitation Department, Minya, Egypt; ⁴Sohag University Hospital, Rheumatology and Rehabilitation, Sohag, Egypt

Background: Ankylosing Spondylitis (AS) is a systemic inflammatory disease of unknown origin. It affects mainly males. Chronic inflammatory back pain is the commonest presenting symptom and regularly develops between 20 and 40 years age. AS can likewise, have extra-articular manifestations. These manifestations commonly develop after the onset of axial symptoms but hardly can precede them. Even though AS is a systemic disease, the presenting symptoms, treatment, and morbidity are largely dependent on spine affection. Epidural injections for managing chronic low back pain are one of the most frequently performed interventions in the United States. Friedly et al reported administration of epidural injections in 36% of patients with axial low back pain. However, there is no clinical evidence for the use of epidural injections in axial SPA and most recommendations are limited to radicular pain with disc herniation. The evidence for caudal epidural injections is Level I in managing pain secondary to disc herniation and radiculitis. To our best of knowledge, this is the first study evaluating the role of caudal epidural steroid and lidocaine injections in managing pain and function of the spine in radiographic axial SPA.

Objectives: To evaluate the significance of caudal epidural injections in controlling pain and spinal stiffness in radiographic axial SPA.

Methods: In our study 32 Patients were included. They were randomly doled out into 2 equivalent groups; Group I received caudal epidural injections ultrasound guided with 1% lidocaine hydrochloride (xylocaine, AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip), whereas Group II did not receive. Both groups were matched regarding age, sex and disease duration (table) and both were under treatment with anti TNF and NSAIDs with or without sDMARDs. All participants fulfilled the ASAS criteria for radiographic axial SPA. Outcomes measures included: visual Analogue Scale (VAS), and ASDAS score with assessment at baseline, 2 weeks and 8 weeks post-treatment. Significant pain relief was defined as 50% or more or no pain. ASDAS improvement is considered when the score reduction ≥ 1.1 .

Results: There was a significant difference between both groups regarding pain (Figure 1) and ASDAS scores (Figure 2) in favor of group I. This effect was maximum after 2 weeks interval. More than two thirds of the cases (68.8%) had significant pain relief among group 1, compared to only 18.8% among group 2. Despite the decline of this effect after 8 weeks, still the difference significant between both groups. Shorter disease duration and older age of onset were associated with better outcomes among group 1 but not group 2. However, these correlations were non-significant.